SEC Form 4
Amylyx Pharmaceuticals, Inc. (AMLX) insider trading
In the 12 months to Nov 14, 2026, 5 AMLX insiders reported open-market sales of $12.3M across 7 filings; one director bought $152.2K.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $12.3M
- 7 filings · 5 insiders
- Open-market purchases
- $152.2K
- 2 filings · Karen Firestone, Director
- Pre-arranged sales (10b5-1)
- 5 of 7
- $8.5M of $12.3M sold (69%)
Who traded AMLX, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
AMLX daily close from Nov 14, 2025 to Nov 13, 2026, between $11.38 and $39.66, last $30.29. 7 sale and 2 purchase filings by 6 insiders, marked at their filing dates. Joshua B. Cohen, Co-Chief Executive Officer: sold $4.9M across 2 filings, first filed Jan 20, 2026, last Nov 12, 2026. Justin B. Klee, Co-Chief Executive Officer: sold $4.9M across 2 filings, first filed Jan 20, 2026, last Nov 12, 2026. James M. Frates, Chief Financial Officer: sold $1.2M across 1 filing, first filed Nov 12, 2026, last Nov 12, 2026. George M. Milne Jr., Director: sold $830.9K across 1 filing, first filed Oct 7, 2026, last Oct 7, 2026. Gina Mazzariello, Chief Legal Officer: sold $538.9K across 1 filing, first filed Jul 13, 2026, last Jul 13, 2026. Karen Firestone, Director: bought $152.2K across 2 filings, first filed Dec 23, 2025, last May 26, 2026.
Largest mark · tap a row for others
Justin B. Klee · Co-Chief Executive Officer
Sale $2,983,838
100,000 shares at $29.84 avg
Filed Nov 12, 2026 · traded Nov 9
Pre-arranged (10b5-1) · close on filing date $29.86
Joshua B. Cohen · Co-Chief Executive Officer
Co-Chief Executive Officer
$4.9M soldJustin B. Klee · Co-Chief Executive Officer
Co-Chief Executive Officer
$4.9M soldJames M. Frates · Chief Financial Officer
Chief Financial Officer
$1.2M soldGeorge M. Milne Jr. · Director
Director
$830.9K soldGina Mazzariello · Chief Legal Officer
Chief Legal Officer
$538.9K soldKaren Firestone · Director
Director
$152.2K boughtOpen-market trades
9 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Joshua B. Cohen | Co-Chief Executive Officer | $4.9M | — | 2 | 61% of sales | |
| Justin B. Klee | Co-Chief Executive Officer | $4.9M | — | 2 | 61% of sales | |
| James M. Frates | Chief Financial Officer | $1.2M | — | 1 | 100% of sales | |
| George M. Milne Jr. | Director | $830.9K | — | 1 | 100% of sales | |
| Gina Mazzariello | Chief Legal Officer | $538.9K | — | 1 | 100% of sales | |
| Karen Firestone | Director | — | $152.2K | 2 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Joshua B. Cohen Co-Chief Executive Officer | SalePre-arranged (10b5-1) | 100,000 | $29.84 | $3.0M | 3,513,123 | |
traded | Justin B. Klee Co-Chief Executive Officer | SalePre-arranged (10b5-1) | 100,000 | $29.84 | $3.0M | 3,513,056 | |
traded | James M. Frates Chief Financial Officer | SalePre-arranged (10b5-1) | 40,000 | $30.19 | $1.2M | 233,625 | |
traded | George M. Milne Jr. Director | SalePre-arranged (10b5-1) | 30,000 | $27.70 | $830.9K | 782,881 | |
traded | Gina Mazzariello Chief Legal Officer | SalePre-arranged (10b5-1) | 30,000 | $17.96 | $538.9K | 179,090 | |
traded | Karen Firestone Director | Purchase | 3,800 | $13.51 | $51.3K | 66,900 | |
traded | Justin B. Klee Co-Chief Executive Officer | Sale | 138,188 | $13.59 | $1.9M | 3,379,398 | |
traded | Joshua B. Cohen Co-Chief Executive Officer | Sale | 138,167 | $13.59 | $1.9M | 3,379,465 | |
traded | Karen Firestone Director | Purchase | 8,100 | $12.45 | $100.8K | 63,100 |
GET /stocks/filings/vX/form-4?tickers=AMLX&filing_date.gte=2025-11-14&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"AMLX"
],
"issuer_cik": "0001658551",
"owner_cik": "0001235598",
"accession_number": "0001193125-26-458247",
"form_type": "4",
"filing_date": "2026-11-12",
"period_of_report": "2026-11-09",
"issuer_name": "Amylyx Pharmaceuticals, Inc.",
"issuer_trading_symbol": "AMLX",
"owner_name": "FRATES JAMES M",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Financial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-11-09",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 7700,
"transaction_price_per_share": 29.3887,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 245925,
"transaction_value": 226292.99,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 10, 2026."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.81 to $29.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."
}
]
},
{
"tickers": [
"AMLX"
],
"issuer_cik": "0001658551",
"owner_cik": "0001235598",
"accession_number": "0001193125-26-458247",
"form_type": "4",
"filing_date": "2026-11-12",
"period_of_report": "2026-11-09",
"issuer_name": "Amylyx Pharmaceuticals, Inc.",
"issuer_trading_symbol": "AMLX",
"owner_name": "FRATES JAMES M",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "Chief Financial Officer",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-11-10",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 12800,
"transaction_price_per_share": 30.3209,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 240825,
"transaction_value": 388107.52,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 10, 2026."
},
{
"id": "F4",
"description": "The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.86 to $30.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 43 records
- Option exercises8 records
- Tax withholding (sold to cover)24 records
- Grants and awards10 records
- Gifts1 record
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Amylyx Pharmaceuticals, Inc.'s CEO sold stock?
Yes. Justin B. Klee (CEO) sold 238,188 shares ($4.9M) between Jan 2026 and Nov 2026, $3.0M of it under a pre-arranged 10b5-1 plan. Joshua B. Cohen (CEO) sold 238,167 shares ($4.9M) between Jan 2026 and Nov 2026, $3.0M of it under a pre-arranged 10b5-1 plan.
How current is AMLX’s insider data?
These are AMLX Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track AMLX insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for AMLX every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.